Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Other

Pulmonary fibrosis drug developer Avalyn files IPO

 April 9, 2026

Pharmaphorum

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

OtherRespiratoryRead full story

Post navigation

Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic →
← Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com